QURE240517P5000
- 0.15
- 0.000.00%
uniQure NV Newsroom
UniQure N.V. (NASDAQ:QURE) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
It's been a good week for uniQure N.V. (NASDAQ:QURE) shareholders, because the company has just released its latest quarterly results, and the shares gained 4.5% to US$4.89. Revenues of US$8.5m
Stifel Nicolaus Sticks to Its Buy Rating for UniQure (QURE)
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
UniQure Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Express News | HC Wainwright & Co. Reiterates Buy on UniQure, Maintains $25 Price Target
Mizuho Adjusts UniQure's Price Target to $6 From $7, Keeps Neutral Rating
Mizuho Adjusts uniQure's Price Target to $6 From $7, Keeps Neutral Rating.
UniQure Price Target Cut to $6.00/Share From $7.00 by Mizuho
UniQure Price Target Cut to $6.00/Share From $7.00 by Mizuho
Express News | Mizuho Maintains Neutral on UniQure, Lowers Price Target to $6
Express News | Uniqure NV : Mizuho Cuts Target Price to $6 From $7
uniQure NV | 10-Q: Quarterly report
Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M
07:27 AM EDT, 05/07/2024 (MT Newswires) -- Earnings Flash (QURE) UNIQURE Reports Q1 Revenue $8.5M
UniQure Expects Cash, Cash Equivalents and Investment Securities Will Fund Ops Into the 2Q of 2027 >QURE
UniQure Expects Cash, Cash Equivalents and Investment Securities Will Fund Ops Into the 2Q of 2027 >QURE
UniQure Comprehensive Review of Ops and Options to Reduce Expenses Underway and Expected to Be Completed in Mid-2024 >QURE
UniQure Comprehensive Review of Ops and Options to Reduce Expenses Underway and Expected to Be Completed in Mid-2024 >QURE
Press Release: UniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress On track to initiate FDA interaction regarding AMT-130 in second quarter of 2024 and provide a clinical u
UniQure 1Q Loss/Shr $1.36 >QURE
UniQure 1Q Loss/Shr $1.36 >QURE
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating
UBS Lowers UniQure's Price Target to $27 From $38, Maintains Buy Rating.
Kyowa Kirin's Rare Disease Therapy Becomes World's Most Expensive Drug
13 Best Biotech Stocks To Buy Under $20
AMD To Rally Around 16%? Here Are 10 Top Analyst Forecasts For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. B of A Sec
UniQure Is Maintained at Neutral by Mizuho
UniQure Is Maintained at Neutral by Mizuho
Express News | Mizuho Maintains Neutral on UniQure, Lowers Price Target to $7